Validated spectrofluorimetric method for the determination of sunitinib malate, dye complexation approach for a novel anticancer drug;Antikanser ilaç sunitinib malat'ın boya ile kompleklestirme yöntemi kullanılarak spektroflorimetrik tayini

Acta Pharmaceutica Sciencia

Volumn 52, Issue 4, 2010, Pages 468-484

  Arici, Mesut ^a   Kilinç, Emrah ^a  

^a EGE UNIVERSITY   (Turkey)

Author keywords

Analytical method validation; Eosin Y; Ion pair complex; Spectrofluorimetric determination; Sunitinib malate

Indexed keywords

EOSIN; SUNITINIB;

ACCURACY; ARTICLE; COMPLEX FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DECOMPOSITION; DRUG DETERMINATION; DRUG STABILITY; DRUG STRUCTURE; INCUBATION TIME; OXYGEN CONCENTRATION; PH MEASUREMENT; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; SPECTROFLUOROMETRY; TEMPERATURE SENSITIVITY; VALIDATION PROCESS;

EID: 79952342236     PISSN: 13072080     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Abdellatef, H.E. (2007). Extractive-spectrophotometric determination of disopyramide and irbesartan in their pharmaceutical formulation. Spectr. Acta Part A 66: 1248-1254.
2. Abrams, T.J., Lee, L.B., Murray, L.J., Pryer, N.K. and Cherrington, J.M. (2003). SU11248 inhibits KIT and plateletderived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol. Cancer Ther. 2: 471-478.
3. Al-Ghannam, S.M. (2006). A simple spectrophotometric method for the determination of beta-blockers in dosage forms. J. Pharm. Biomed. Anal. 40: 151-156.
4. Arancibia, J.A. and Escandar, G.M. (1999). Complexation study of diclofenac with beta-cyclodextrin and spectrofluorimetric determination. Analyst. 124: 1833-1838.
5. Barattè, S., Sarati, S., Frigerio, E., James, C. A., Ye, C. and Zhang, Q. (2004). Quantitation of SU1 1248, an oral multi-target tyrosine kinase inhibitor, and its metabolite in monkey tissues by liquid chromatograph with tandem mass spectrometry following semi-automated liquid-liquid extraction. J. Chromatogr. A. 1024: 87-94.
6. Belal, F., Abdine, H., Al-Majed, A. and Khalil, N.Y. (2002). Spectrofluorimetric determination of vigabatrin and gabapentin in urine and dosage forms through derivatization with fluorescamine. J. Pharm. Biomed. Anal. 27: 253-260.
7. Blanchet, B., Saboureau, C., Benichou, A.S., Billemont, B., Taieb, F., Ropert, S., Dauphin, A., Goldwasser, F., Tod, M. (2009). Development and validation of an HPLC-UV-visible method for sunitinib quantification in human plasma.Clin. Chim. Acta. 404: 134-139.
8. Damiani, P.C., Bearzotti, M., Cabezón, M. and Olivieri, A.C. (1998). Spectrofluorometric determination of piroxicam. J. Pharm. Biomed. Anal. 17: 233-236.
9. Damiani, P.C., Bearzotti, M., Cabezón, M.A. and Olivieri, A.C. (1999). Spectrofluorometric determination of diclofenac in tablets and ointments. J. Pharm. Biomed. Anal. 20: 587-590.
10. Dinesh, N.D., Nagaraja, P., Made Gowda, N.W. and Rangappa, K.S. (2002). Extractive spectrophotometric methods for the assay of sildenafil citrate (Viagra) in pure form and in pharmaceutical formulations. Talanta 57: 757-764.
11. El-Brashy, A.M., El-Sayed Metwally, M. and El-Sepai, F.A. (2004). Spectrophotometric determination of some fluoroquinolone antibacterials by binary complex formation with xanthene dyes. Farmaco. 59: 809-817.
12. El-Shiekh, R., Zahran, F. and El-Fetouh Gouda, A.A. (2007). Spectrophotometric determination of some anti-tussive and anti-spasmodic drugs through ion-pair complex formation with thiocyanate and cobalt(II) or molybdenum(V). Spectr. Acta Part A. 66: 1279-1287.
13. Ermer, J. and Ploss, H.J. (2005). Validation in pharmaceutical analysis. Part II: Central importance of precision to establish acceptance criteria and for verifying and improving the quality of analytical data. J. Pharm. Biomed. Anal. 37: 859-870.
14. Escandar, G.M. (1999a). Spectrofluorimetric determination of piroxicam in the presence and absence of betacyclodextrin. Analyst 124: 587-591.
15. Escandar, G.M. (1999b). Spectroscopic study of salicylate-cyclodextrin systems in the presence and absence of alcohols. Spectr. Acta Part A 55: 1743-1752. FDA labelling information, http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108583 .htm, 2006, Accessed 17.08.2010.
16. Fiedler, W., Serve, H., Döhner, H., Schwittay, M., Ottmann, O.G., O'Farrell, A.-M., Bello, C.L., Allred, R., Manning, W.C, Cherrington, J.M., Louie, S.G., Hong, W., Brega, N.M., Massimini, G., Scigalla, P., Berdel, W.E. and Hossfeld, D.K. (2005). A Phase 1 study of SU-11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 105: 986-993.
17. th International Symposium on Chromatography, Leipzig.
18. Hefnawy, M., El-Shabrawy, Y. and Belal, F. (1999). Spectrofluorometric determination of alpha-aminocephalosporins in biological fluids and pharmaceutical preparations. J. Pharm. Biomed. Anal. 21: 703-707.
19. ICH - International Conference on Harmonization of Technical Requirements for the Registration of Pharmaceuticals for Human Use. Guideline Q2(R1)-Validation of Analytical Procedures: Text and Methodology 2005; ICH Secretariat, c/o IFPMA, Geneva- Switzerland. 1-13.
20. Kelani, K., Bebawy, L.I. and Abdel-Fattah, L. (1999). Determination of astemizole, terfenadine and flunarizine hydrochloride by ternary complex formation with eosin and lead(II). J. Pharm. Biomed. Anal. 18: 985-992.
21. Mendel, D.B., Laird, A.D., Xin, X., Louie, S.G., Christensen, J.G., Li, G., Schreck, R.E., Abrams, T.J., Ngai, T.J., Lee, L.B., Murray, L.J., Carver, J., Chan, E., Moss, K.G., Haznedar, J.O., Sukbuntherng, J., Blake, R.A., Sun, L., Tang, C., Miller, T., Shirazian, S., McMahon, G. and Cherrington, J.M. (2003). In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 9: 327-337
22. Minkin, P., Zhao, M., Chen, Z., Ouwerkerk, J., Gelderblom, H. and Baker, S.D. (2008). Quantification of sunitinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr. B Analyt. Technol. Biomed. Life Sci. 874: 84-88.
23. Moustafa, A.A. (2000). Spectrophotometric methods for the determination of lansoprazole and pantoprazole sodium sesquihydrate. J. Pharm. Biomed. Anal. 22: 45-58.
24. Prabhakar, A.H., Patel, V.B. and Giridhar, R. (1999). Spectrophotometric determination of fluoxetine hydrochloride in bulk and in pharmaceutical formulations. J. Pharm. Biomed. Anal. 20: 427-432.
25. Süslü, I. and Tamer, A. (2002). Spectrophotometric determination of enoxacin as ion-pairs with bromophenol blue and bromocresol purple in bulk and pharmaceutical dosage form. J. Pharm. Biomed. Anal. 29: 545-554.